• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为一种源自术前FDG PET/CT的生物标志物,口腔鳞状细胞癌中的总病变糖酵解在新开发的多变量预测模型中优于既定的预后因素。

Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model.

作者信息

Spanier Gerrit, Weidt Daniela, Hellwig Dirk, Meier Johannes K H, Reichert Torsten E, Grosse Jirka

机构信息

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.

Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.

出版信息

Oncotarget. 2021 Jan 5;12(1):37-48. doi: 10.18632/oncotarget.27857.

DOI:10.18632/oncotarget.27857
PMID:33456712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7800778/
Abstract

PURPOSE

Retrospective study to investigate the impact of image derived biomarkers from [F]FDG PET/CT prior to surgical resection in patients with initial diagnosis of oral squamous cell carcinoma (OSCC), namely SUV, SUV, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary tumor to predict overall survival (OS).

MATERIALS AND METHODS

127 subsequent patients with biopsy-proven OSCC were included who underwent [F]FDG PET/CT before surgery. SUV, SUV, MTV and TLG of the primary tumor were measured. OS was estimated according to Kaplan-Meier and compared between median-splitted groups by the log-rank test. Prognostic parameters were analyzed by uni-/multivariate Cox-regression.

RESULTS

During follow-up 52 (41%) of the patients died. Median OS was longer for patients with lower MTV or lower TLG. SUV and SUV failed to be significant predictors for OS. Univariate Cox-regression identified MTV, TLG, lymph node status and UICC stage as prognostic factors. By multivariate Cox-regression MTV and TLG turned out to be independent prognostic factors for OS.

CONCLUSIONS

The pre-therapeutic [F]FDG PET/CT parameters MTV and TLG in the primary tumor are prognostic for OS of patients with an initial diagnosis of OSCC. TLG is the strongest independent prognostic factor for OS and outperforms established prognostic parameters in OSCC.

摘要

目的

进行回顾性研究,以探讨在初诊为口腔鳞状细胞癌(OSCC)的患者手术切除前,[F]FDG PET/CT图像衍生生物标志物,即原发肿瘤的SUV、SUV、代谢肿瘤体积(MTV)和总病变糖酵解(TLG)对总生存期(OS)的预测作用。

材料与方法

纳入127例经活检证实为OSCC且术前接受[F]FDG PET/CT检查的患者。测量原发肿瘤的SUV、SUV、MTV和TLG。根据Kaplan-Meier法估计总生存期,并通过对数秩检验比较中位数分割组之间的差异。通过单因素/多因素Cox回归分析预后参数。

结果

随访期间52例(41%)患者死亡。MTV或TLG较低的患者中位总生存期较长。SUV和SUV未能成为总生存期的显著预测指标。单因素Cox回归分析确定MTV、TLG、淋巴结状态和国际抗癌联盟(UICC)分期为预后因素。多因素Cox回归分析显示MTV和TLG是总生存期的独立预后因素。

结论

原发肿瘤的治疗前[F]FDG PET/CT参数MTV和TLG对初诊为OSCC患者的总生存期具有预后价值。TLG是总生存期最强的独立预后因素,优于OSCC中已确立的预后参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/b454ff2350f8/oncotarget-12-37-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/bf34d058137b/oncotarget-12-37-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/6b0424792b62/oncotarget-12-37-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/b454ff2350f8/oncotarget-12-37-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/bf34d058137b/oncotarget-12-37-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/6b0424792b62/oncotarget-12-37-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8963/7800778/b454ff2350f8/oncotarget-12-37-g003.jpg

相似文献

1
Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model.作为一种源自术前FDG PET/CT的生物标志物,口腔鳞状细胞癌中的总病变糖酵解在新开发的多变量预测模型中优于既定的预后因素。
Oncotarget. 2021 Jan 5;12(1):37-48. doi: 10.18632/oncotarget.27857.
2
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.预处理代谢肿瘤体积和 18F-FDG PET/CT 总病变糖酵解对接受抗血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者的预后价值。
Clin Nucl Med. 2017 May;42(5):e235-e241. doi: 10.1097/RLU.0000000000001612.
3
Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.(18)F-FDG PET/CT 测量的术前代谢肿瘤体积和总病变糖酵解对口腔鳞状细胞癌的预后意义。
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):452-61. doi: 10.1007/s00259-013-2571-z. Epub 2013 Oct 1.
4
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.术前 ¹⁸F-FDG PET/CT 代谢肿瘤体积和总病变糖酵解对胰腺癌患者的预后价值。
J Nucl Med. 2014 Jun;55(6):898-904. doi: 10.2967/jnumed.113.131847. Epub 2014 Apr 7.
5
Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.证实术前肿瘤 SUR 和 MTV 对食管鳞癌患者的预后价值。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1485-1494. doi: 10.1007/s00259-019-04307-6. Epub 2019 Apr 4.
6
Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.标准化摄取值和代谢肿瘤体积在¹⁸F-FDG PET/CT上对口咽鳞状细胞癌的预后意义
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12.
7
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.基于基线 18F-FDG PET/CT 的各种代谢参数在接受铂类化疗的非小细胞肺癌患者中的作用作为预后标志物。
Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886.
8
[Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].[预处理(18)F-FDG PET-CT对晚期弥漫性大B细胞淋巴瘤患者的预后价值]
Zhonghua Zhong Liu Za Zhi. 2018 Jul 23;40(7):528-533. doi: 10.3760/cma.j.issn.0253-3766.2018.07.009.
9
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.(18)F-FDG PET 代谢肿瘤负荷对非小细胞肺癌手术患者的预后价值。
Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.
10
Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.预处理 18F-FDG PET/CT 测量的容积参数对皮肤恶性黑色素瘤患者的预后价值。
Clin Nucl Med. 2016 Jun;41(6):e266-73. doi: 10.1097/RLU.0000000000001205.

引用本文的文献

1
F-FDG PET/CT-derived total lesion glycolysis predicts abscess formation in patients with surgically confirmed infective endocarditis: Results of a retrospective study at a tertiary center.F-FDG PET/CT 衍生的总病变糖酵解预测手术确诊感染性心内膜炎患者脓肿形成:来自三级中心的回顾性研究结果。
J Nucl Cardiol. 2023 Dec;30(6):2400-2414. doi: 10.1007/s12350-023-03285-5. Epub 2023 Jun 1.
2
Advances in Image-Guided Radiotherapy in the Treatment of Oral Cavity Cancer.口腔癌影像引导放射治疗的进展
Cancers (Basel). 2022 Sep 23;14(19):4630. doi: 10.3390/cancers14194630.
3
Salivary Metabolomics for Prognosis of Oral Squamous Cell Carcinoma.

本文引用的文献

1
Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer: A Systematic Review.评估 FDG PET/CT 参数对手术治疗头颈部癌症患者预后的价值:系统评价。
JAMA Otolaryngol Head Neck Surg. 2020 May 1;146(5):471-479. doi: 10.1001/jamaoto.2020.0014.
2
HPV, protein p16 and squamous cell carcinoma of the oral cavity.人乳头瘤病毒、p16蛋白与口腔鳞状细胞癌
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):292-299. doi: 10.5507/bp.2019.026. Epub 2019 Jun 17.
3
Low prevalence of HPV-induced oral squamous cell carcinoma in Geneva, Switzerland.
唾液代谢组学用于口腔鳞状细胞癌的预后评估
Front Oncol. 2022 Jan 5;11:789248. doi: 10.3389/fonc.2021.789248. eCollection 2021.
4
Implications of Standardized Uptake Values of Oral Squamous Cell Carcinoma in PET-CT on Prognosis, Tumor Characteristics and Mitochondrial DNA Heteroplasmy.PET-CT中口腔鳞状细胞癌标准化摄取值对预后、肿瘤特征及线粒体DNA异质性的影响
Cancers (Basel). 2021 May 10;13(9):2273. doi: 10.3390/cancers13092273.
瑞士日内瓦 HPV 诱发的口腔鳞状细胞癌发病率低。
Oral Dis. 2019 Jul;25(5):1283-1290. doi: 10.1111/odi.13084. Epub 2019 Apr 2.
4
Imaging of Patients with Head and Neck Cancer: From Staging to Surveillance.头颈部癌症患者的影像学检查:从分期到监测
Oral Maxillofac Surg Clin North Am. 2018 Nov;30(4):421-433. doi: 10.1016/j.coms.2018.06.004. Epub 2018 Aug 22.
5
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.代谢肿瘤体积用于晚期霍奇金淋巴瘤的疗效预测
J Nucl Med. 2018 Jun 7;60(2):207-11. doi: 10.2967/jnumed.118.210047.
6
PET/CT and PET/MRI in head and neck malignancy.头颈部恶性肿瘤的正电子发射断层显像/计算机断层扫描(PET/CT)及正电子发射断层显像/磁共振成像(PET/MRI)
Clin Radiol. 2018 Jan;73(1):60-69. doi: 10.1016/j.crad.2017.09.001. Epub 2017 Oct 10.
7
Revisiting the hallmarks of cancer.重探癌症的特征
Am J Cancer Res. 2017 May 1;7(5):1016-1036. eCollection 2017.
8
Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.瘤内代谢异质性及定量18F-FDG PET/CT参数对预测人乳头瘤病毒阳性的原发性口咽鳞状细胞癌患者预后的价值
Clin Nucl Med. 2017 May;42(5):e227-e234. doi: 10.1097/RLU.0000000000001578.
9
Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.头颈部肿瘤—美国癌症联合委员会第八版癌症分期手册的重大变化。
CA Cancer J Clin. 2017 Mar;67(2):122-137. doi: 10.3322/caac.21389. Epub 2017 Jan 27.
10
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.